Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
ELH Spierings, JL Brandes, DB Kudrow… - …, 2018 - journals.sagepub.com
Objective To determine the efficacy, tolerability, and safety of ascending doses of Adhesive
Dermally-Applied Microarray (ADAM) zolmitriptan versus placebo for acute migraine
treatment. Background ADAM is a novel patient-administered system for intracutaneous
drug administration. In a phase 1 pharmacokinetic study, zolmitriptan administered using
ADAM had much faster absorption than oral administration with higher exposure in the first
two hours. Methods This was a multicenter, randomized, double-blind, placebo-controlled …
Dermally-Applied Microarray (ADAM) zolmitriptan versus placebo for acute migraine
treatment. Background ADAM is a novel patient-administered system for intracutaneous
drug administration. In a phase 1 pharmacokinetic study, zolmitriptan administered using
ADAM had much faster absorption than oral administration with higher exposure in the first
two hours. Methods This was a multicenter, randomized, double-blind, placebo-controlled …
A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic …
RJ Soman, MV Swamy - International Journal of Colorectal Disease, 2019 - Springer
Purpose This prospective, randomized, double-blind, placebo-controlled, parallel-group
study aimed to determine the efficacy and safety of a multistrain (Bacillus coagulans [SNZ
1969], Bacillus clausii [SNZ 1971], and Bacillus subtilis [SNZ 1972]) probiotic blend (SNZ
TriBac) in managing symptoms of gastrointestinal (GI) discomfort in the absence of specific
pathologies. Methods Sixty adults with symptoms of GI discomfort were enrolled (mean age,
34.89±9.95 years) and randomized to receive either SNZ TriBac or placebo. Changes from …
study aimed to determine the efficacy and safety of a multistrain (Bacillus coagulans [SNZ
1969], Bacillus clausii [SNZ 1971], and Bacillus subtilis [SNZ 1972]) probiotic blend (SNZ
TriBac) in managing symptoms of gastrointestinal (GI) discomfort in the absence of specific
pathologies. Methods Sixty adults with symptoms of GI discomfort were enrolled (mean age,
34.89±9.95 years) and randomized to receive either SNZ TriBac or placebo. Changes from …
以上显示的是最相近的搜索结果。 查看全部搜索结果